Pharma business info

Swiss pharma giant Novartis stated that it was recalling four different medications sold over the counter in the US market following reports of a malfunction at one of its facilities.

Synta Pharmaceuticals is offering 7 million scrips of common stock to the public, with the prospective of making net income of $28.6 million, the company said.

Savient Pharmaceuticals declared that a product-specific billing system, or lasting J-code, for KRYSTEXXA® (pegloticase) became accessible on January 1, 2012.

Endo Pharmaceuticals has decided to pay around $180 million for licensing rights
to sell a potential pain cure from BioDelivery Sciences International Inc.